Literature DB >> 3079493

Does chemotherapy benefit the patient with a central nervous system glioma?

L A Rodriguez1, V A Levin.   

Abstract

The authors discuss the results of clinical trials assessing the value of chemotherapy for brain tumors in the adjuvant setting as well as at recurrence. Adjuvant chemotherapy does benefit some patients with malignant brain gliomas. Improved survival rates seem to be related to an increased number of long-term survivors. The most effective chemotherapy is BCNU or a combination of CCNU, procarbazine, and vincristine (PCV). Drugs that potentiate radiation therapy, such as hydroxyurea and BUdR, are also useful in some patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3079493

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  6 in total

1.  Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.

Authors:  Ali Chahlavi; Andrew Kanner; David Peereboom; Susan M Staugaitis; Paul Elson; Gene Barnett
Journal:  J Neurooncol       Date:  2003-02       Impact factor: 4.130

2.  Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.

Authors:  Jean-Blaise Wasserfallen; Sandrine Ostermann; Serge Leyvraz; Roger Stupp
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

3.  VP-16, vincristine and procarbazine with radiation therapy for treatment of malignant brain tumors.

Authors:  R M Hellman; J A Calogero; B M Kaplan
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

4.  A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas--an Eastern Cooperative Oncology Group Study (E2392).

Authors:  R Hellman; D S Neuberg; H Wagner; M Grunnet; H I Robins; D Karp; P Flynn; G Adams
Journal:  J Neurooncol       Date:  1998-03       Impact factor: 4.130

5.  In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines.

Authors:  T Coyle; S Levante; M Shetler; J Winfield
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.

Authors:  E S Newlands; T Foster; S Zaknoen
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.